Tumor Marker Testing Market Growth Outlook Indicating Expansion To $27.23 Billion By 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Market Value Trend Is Expected For The Tumor Marker Testing Market From 2026 To 2030?

The tumor marker testing market size has demonstrated significant growth in recent years. It is projected to increase from $18.6 billion in 2025 to $20.12 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.2%. The expansion observed in the historic period is attributable to escalating cancer incidence rates, the wider adoption of laboratory diagnostics in oncology, the expansion of hospital-based cancer testing services, the availability of established biochemical markers, and the proliferation of diagnostic laboratory networks.

The tumor marker testing market size is projected to experience substantial expansion over the upcoming years. It is anticipated to grow to $27.23 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.9%. The projected growth can be attributed to a rising demand for early cancer detection, the increasing adoption of precision oncology approaches, an expansion of companion diagnostics, the growing use of biomarkers in therapy selection, and advancements in cancer biomarker research. Major trends expected in the forecast period include the increasing adoption of multiplex tumor marker panels, a rising use of blood-based cancer diagnostics, the growing integration of tumor markers in treatment monitoring, an expansion of early cancer screening programs, and an enhanced focus on personalized oncology care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20668&type=smp

What Important Drivers Are Powering The Tumor Marker Testing Market Growth?

The growing occurrence of cancer is projected to stimulate the expansion of the tumor marker testing market in the coming years. Cancer is a condition marked by the unrestricted proliferation of atypical cells within the body. These cells possess the capability to infiltrate adjacent tissues and disseminate to various bodily regions via the circulatory and lymphatic systems. The rise in cancer incidents can be attributed to factors like an aging demographic, heightened exposure to environmental elements, evolving lifestyle choices, and advancements in screening and identification methods. Tumor marker testing serves the purpose of diagnosing, observing the effectiveness of treatment, and identifying the re-occurrence of different cancers through the measurement of distinct substances generated by malignant cells. For instance, in October 2025, as reported by the National Health Service, a Uk-based government agency, in 2023, there were 354,820 new cancer diagnoses, equating to 972 per day on average, which was 8,605 more than in 2022. Consequently, the rising prevalence of cancer is fueling the growth of the tumor marker testing market.

Which Segment Divisions Form The Structure Of The Tumor Marker Testing Market?

The tumor marker testing market covered in this report is segmented –

1) By Product: Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines

2) By Methods: Screening, Imaging, Theranostics, Other Methods

3) By Application: Hospitals, Commercial Or Private Laboratories, Physician Offices Or Group Practices, Cancer Clinics, Ambulatory Care Centers

Subsegments:

1) By Biochemical Markers: Alpha-fetoprotein (AFP), Prostate-Specific Antigen (PSA), Carcinoembryonic Antigen (CEA), Cancer Antigen 125 (CA 125), Cancer Antigen 19-9 (CA 19-9), Human Chorionic Gonadotropin (hCG)

2) By Oncogenes: HER2 Or neu, KRAS, BRAF, EGFR (Epidermal Growth Factor Receptor), c-MYC, p53

3) By Growth Factors: Vascular Endothelial Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Fibroblast Growth Factor (FGF), Insulin-like Growth Factor (IGF)

4) By Hormones: Estrogen Receptors (ER), Progesterone Receptors (PR), Thyroglobulin, Calcitonin, Adrenocorticotropic Hormone (ACTH), Gastrin

5) By Colony Stimulating Factors: Granulocyte Colony-Stimulating Factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Macrophage Colony-Stimulating Factor (M-CSF)

6) By Lymphokines: Interleukin-2 (IL-2), Interferon-gamma (IFN-γ), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6)

What Trends Are Shaping The Tumor Marker Testing Market Structure?

Prominent companies operating within the tubular external fixation system market are prioritizing the development of advanced solutions, such as stable external fixation systems, to improve patient outcomes and boost the efficiency of orthopedic treatments. A stable external fixation system is a medical apparatus that externally immobilizes and stabilizes fractures, ensuring accurate bone alignment throughout the healing phase. For example, in September 2023, Orthofix Medical Inc., a US-based spine and orthopedics company, introduced the Galaxy Fixation Gemini system, a new stable external fixation system specifically designed for addressing fractures resulting from trauma in both lower and upper limbs. This system is distinguished by its availability in multiple sterile procedure kit configurations, offering a rapid, ready-to-use solution for medical professionals. This innovative system incorporates sterile procedure kits that eliminate the requirement for tray sterilization, leading to considerable reductions in costs and operating room delays. The system thereby enhances operational efficiency and is well-suited for swift deployment in trauma environments, making it a valuable addition to Orthofix’s array of procedural solutions.

Which Firms Are Competing In The Tumor Marker Testing Market?

Major companies operating in the tumor marker testing market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Danaher Corporation, Siemens Healthineers AG, Becton Dickinson and Company (BD), Quest Diagnostics Inc., Agilent Technologies Inc, Hologic Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., Qiagen N.V., DiaSorin S.p.A., Myriad Genetics, Ortho Clinical Diagnostics PLC, Veracyte Inc., Biodesix Inc., Biocept Inc., Proteomedix AG, OncoCyte Corporation, Biocartis NV

Access The Complete Tumor Marker Testing Market Report:

https://www.thebusinessresearchcompany.com/report/tumor-marker-testing-global-market-report

Which Region Commands The Largest Share Of The Tumor Marker Testing Market?

North America was the largest region in the tumor marker testing market in 2025. The regions covered in the tumor marker testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Tumor Marker Testing Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=20668&type=smp

Browse Through More Reports Similar to the Global Tumor Marker Testing Market 2026, By The Business Research Company

Circulating Tumor Cells Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/circulating-tumor-cells-global-market-report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-necrosis-factor-inhibitor-drugs-global-market-report

Tumor Infiltrating Lymphocytes Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/tumor-infiltrating-lymphocytes-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795